## **Core Concept**
The question tests the understanding of thrombolytic agents and their mechanism of action, specifically those that activate plasmin. Thrombolytic agents are used to dissolve blood clots and are crucial in the management of conditions like acute ischemic stroke, pulmonary embolism, and myocardial infarction. Plasmin is a key enzyme involved in fibrinolysis, the process of breaking down blood clots.

## **Why the Correct Answer is Right**
The correct answer, **C. Alteplase (tPA)**, works by directly activating plasminogen to form plasmin. Plasmin then degrades fibrin clots into fibrin degradation products, effectively dissolving the clot. Alteplase, a tissue plasminogen activator (tPA), has a high affinity for fibrin and preferentially activates plasminogen that is bound to fibrin, which helps to localize the clot lysis and reduce systemic bleeding risks.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Streptokinase works by forming a complex with plasminogen, which then activates another plasminogen molecule to form plasmin. It does not directly activate plasmin but works indirectly by activating plasminogen.
- **Option B:** Urokinase directly activates plasminogen to plasmin but is not as fibrin-specific as alteplase, leading to a higher risk of systemic bleeding.
- **Option D:** Reteplase is also a plasminogen activator but is a mutant form of tPA with a longer half-life. Like alteplase, it activates plasminogen but is not highlighted for direct plasmin activation specificity in a way that distinguishes it significantly in this context.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that alteplase (tPA) is a fibrin-specific agent, which means it preferentially dissolves clots without causing significant systemic fibrinolysis, reducing the risk of bleeding compared to non-fibrin-specific agents like streptokinase.

## **Correct Answer:** . Alteplase (tPA)